Sarilumab
REQUEST MORE INFO
Price:
US$464.00
(Size: 100 µg)
Click on the image to see the image legend
Sarilumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL6R/CD126, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Sarilumab is a fully human anti-IL-6R monoclonal IgG1 antibody that binds to both membrane bound and soluble interleukin 6 (IL-6) receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6 1. Sarilumab was developped by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe Rheumatoid Arthritis (RA) in combination with methotrexate 4. RA is a chronic inflammatory disease characterized by polyarthritis and its treatment has been challenged by the different response in every patient 3. Subcutaneous administration of Sarilumab has been shown to decrease acute-phase reactant levels and improve in clinical RA symptoms 2.
Target |
IL6R/CD126 |
Clonality |
Monoclonal |
Reactivity |
Human |
Expression |
Recombinant |
Tested Applications |
ELISA, WB |
Host |
Human |
Recommended dilutions |
Optimal dilutions/concentrations should be determined by the end user. |
Conjugation |
Unconjugated |
Isotype |
IgG1 Kappa |
Form |
Liquid |
Purity |
> 95% |
Purification |
Purified from cell culture supernatants by Protein A/G chromatography. |
Storage |
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Buffer |
0.01 M PBS. pH 7.4. |
CAS Number |
1189541-98-7 |
Concentration |
Batch-dependent, typically between 0.5-2.0 mg/ml. |
Availability |
Shipped within 7-12 working days. |
Note |
This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Research Articles on IL6R/CD126